ArticleCancers2023

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1

Marica De Cicco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.